Document is current

Article History

Received: 28 July 2025

Accepted: 13 March 2026

First Online: 8 April 2026

Competing interests

: DE reports disclosures caused by honoraria (Angelini, AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Roche, Sirius Medical), consulting or advisory role (AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Roche, Sirius Medical; Research Funding: Sirius Medical, Dr. Schär). SG reports disclosures caused by honoraria (Novartis, Roche, BMS, AstraZeneca, MSD, Pfizer, Lilly, Seagen, Daiichi Sankyo, Janssen, Gilead), consulting or advisory role (Roche, Novartis, BMS, Pfizer, Lilly, AstraZeneca, Astellas, MSD, Seagen, Daiichi Sankyo, Stemline Therapeutics, Bayer), funding (Roche, Daiichi Sankyo, Novartis, Pfizer, Caris Life Sciences, Lilly, Seagen, Gilead, AstraZeneca, Stemline Therapeutics), travel/accommodations/expenses (Roche, Amgen, Novartis, Pfizer, Bayer, Celgene, Daiichi Sankyo, Janssen, Gilead). GR reports disclosures caused by honoraria (AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Roche, Seagen, Stemline), consulting or advisory role (AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Stemline), research funding (AstraZeneca, Daiichi Sankyo, Stemline) travel/accommodations/expenses (Daiichi Sankyo, Gilead, Roche, Servier). CS reports disclosures caused by travel and research grants and unrestricted grants (Amgen, AstraZeneca, Daiichi-Sankyo, Gilead, Novartis, Pfizer, Stemline). GF reports disclosures caused by grant and honoraria (Pfizer, Roche, AstraZeneca, Gilead, Novartis, MenariniStemline, MSD, Daiichi Sankyo, Lilly, Seagen). RB reports disclosures caused by advisory role (AstraZeneca, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Puma, Roche, Seagen, Stemline), lecture honoraria (AstraZeneca, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, MedMedia, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline), research support (AstraZeneca, Daiichi-Sankyo). EP reports disclosures caused by lecture honoraria and advisory boards (Roche, GSK, MSD, AstraZeneca). ZBH reports disclosures caused by lecture honoraria (MSD, Astra Zeneca, Gilead, Abbvie, Daiichi Sankyo), advisory board (Astra Zeneca, MSD, Stemline, Gilead, Abbvie). MF reports disclosures caused by honoraria (AstraZeneca, Eli Lilly). MG reports disclosures caused by honoraria/travel support (Amgen, AstraZeneca, Bayer, DaiichiSankyo, EliLilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte). EH reports disclosures caused by unrelated funding (Illumina, Roche, Servier, and PreAnalyti), honoraria: Roche, Astra Zeneca), advisory boards (Incyte). DH, GH, AP, ASK, KF, QZ, RG, SH, ND, MB declare no competing interests.